Premium
Efficacy of aminohydroxypropylidene diphosphonate in the treatment of malignancy‐associated hypercalcaemia
Author(s) -
Stevens Mark J.
Publication year - 1987
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.1987.tb120238.x
Subject(s) - hypercalcaemia , malignancy , medicine , hydroxyproline , bone resorption , urology , calcium , gastroenterology , resorption , endocrinology
Two patients with symptomatic malignancy‐associated hypercalcaemia were treated with intravenously‐administered aminohydroxypropylidene diphosphonate (APD). Both patients demonstrated dramatic falls in serum calcium concentration, and in urinary calcium and hydroxyproline excretion that were consistent with a reduction in the rate of bone resorption. Normocalcaemia occurred by day 5 and persisted for approximately three weeks after treatment. No significant side‐effects were encountered. It was concluded that APD is a promising new agent in the management of hypercalcaemia that is associated with malignant disease and warrants further investigation.